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Recently, several in vitro studies have shown that GPR40 receptor activation by free fatty acids (FFAs) results in glucose-dependent
insulin secretion. However, whether GPR40 receptor activation results in glucose-dependent insulin secretion in vivo in rats is not known.
Therefore, we evaluated the effect of synthetic GPR40 receptor agonist (compound 1) on glucose tolerance test (GTT) in fed, fasted, and
insulin-resistant rats. In oral GTT, intraperitoneal GTT, and intravenous GTT, GPR40 receptor agonist improved glucose tolerance, which
was associated with increase in plasma insulin level. Interestingly, in GTTs, the rise in insulin levels in agonist-treated group was directly
proportional to the rate of rise and peak levels of glucose in control group. Although glibenclamide, a widely used insulin secretogogue,
improved glucose tolerance in all GTTs, it did not display insulin release in intraperitoneal GTT or intravenous GTT. In the absence of
glucose load, GPR40 receptor agonist did not significantly change the plasma insulin concentration, but did decrease the plasma glucose
concentration. Fasted rats exhibited impaired glucose-stimulated insulin secretion (GSIS) as compared with fed rats. Compound 1 potentiated
GSIS in fasted state but failed to do so in fed state. Suspecting differential pharmacokinetics, a detailed pharmacokinetic evaluation was
performed, which revealed the low plasma concentration of compound 1 in fed state. Consequently, we examined the absorption profile of
compound 1 at higher doses in fed state; and at a dose at which its absorption was comparable with that in fasted state, we observed
significant potentiation of GSIS. Chronic high-fructose (60%) diet feeding resulted in impaired glucose tolerance, which was improved by
GPR40 receptor agonist. Therefore, our results demonstrate for the first time that acute GPR40 receptor activation leads to potentiation of
GSIS in vivo and improves glucose tolerance even in insulin-resistant condition in rats. Taken together, these results suggest that GPR40
receptor agonists could be potential therapeutic alternatives to sulfonylureas.
© 2009 Elsevier Inc. All rights reserved.1. Introduction
Glucose-stimulated insulin secretion (GSIS) is compro-
mised in conditions of starvation as well as in pathophysio-
logic conditions like impaired glucose tolerance and type 2
diabetes mellitus [1-3]. Glucose-stimulated insulin secretion
occurs through the classic glucose and free fatty acid (FFA)–
mediated pathways. The classic glucose pathway is a KATP-
dependent Ca2+-mediated process. On the other hand, FFA-
mediated insulin secretion results from intracellular utiliza-
tion of fatty acids through the malonyl coenzyme A (CoA)/⁎ Corresponding author. Tel.: +91 22 3081 8404; fax: +91 22 3081
8411.
E-mail address: kumar.nemmani@piramal.com (K.V.S. Nemmani).
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doi:10.1016/j.metabol.2008.10.005long-chain CoA signaling network and triglyceride/FFA
cycling pathway [4]. A recent study demonstrated that FFAs
act as endogenous ligand for extracellularly located GPR40
receptor [5].
GPR40 belongs to class A (rhodopsin-like) of the
superfamily of G-protein–coupled receptors and is preferen-
tially expressed on pancreatic β-cells [6]. In vitro activation
of GPR40 receptor by FFAs has been shown to potentiate
GSIS [7-9]. Studies in MIN6 and INS-1 cells indicate that
saturated, monounsaturated, and polyunsaturated (medium
and long chain) fatty acids augment GSIS through GPR40
receptor activation [5,10]. Furthermore, silencing of GPR40
receptor expression by small interfering RNA in rat islet [11]
and in INS-1 cells led to significant inhibition of FFA-
induced insulin secretion [10]. In GPR40−/− knockout mice,
intralipid infusion-induced insulin secretion was reduced
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C57BL/6J mice [12]. All these studies together underscore
the role of GPR40 as an FFA receptor and its effect on GSIS.
Moreover, a recent study has shown that GPR40 receptor
activation using synthetic molecule causes glucose-depen-
dent insulin secretion in MIN6 cells [13]. Thus, GPR40
receptor agonists could serve as potential therapeutic
alternative to sulfonylureas, which cause insulin release
independent of glucose stimulus causing a prolonged
hypoglycemia that limits their clinical use.
Based on the findings that GPR40 receptor activation
potentiates GSIS in vitro, we designed a study to determine
the effect of GPR40 receptor activation on GSIS in vivo in
rat using small molecule agonist compound 1 [14].
Compound 1 is a full GPR40 receptor agonist and binds to
hGPR40 receptors cloned in Chinese hamster ovary cell lines
with a pEC50 of 6.03 ± 0.04 μmol/L [14]. It is well known
that FFA-mediated GSIS is impaired in fasting conditions
during which it is preferentially subjected to β-oxidation,
thereby limiting its availability to stimulate insulin secretion
[1]. However, it is not known whether potentiation of GSIS
occurring through GPR40 receptor–mediated mechanisms is
altered in fasting states. Hence, our second objective was to
compare the potentiation of GSIS by GPR40 receptor agonist
in fasted and fed states. It is also well known that FFAs
exhibit dual effect on GSIS. Acute exposure of β-cells to
fatty acids potentiates GSIS [15], whereas long-term
exposure inhibits the process [16,17]. Indeed, prolonged
elevation of FFA by chronic feeding of high-fructose diet to
rats results in reduced GSIS [18]. Therefore, our third
objective was to study whether GPR40 receptor agonist
potentiates GSIS in rats chronically fed with 60% high-
fructose diet. When we submitted our work, no study
examining the effect of small molecule GPR40 receptor
agonist in vivo was reported. While this article was under
review, Tan and associates [19] reported that small molecule
GPR40 receptor agonist enhances glucose-dependent insulin
secretion in isolated islets and improves glucose tolerance in
mice. In contrast to in vitro studies on glucose-dependent
insulin secretion by Tan and associates [19], this study has
extensively investigated GSIS in vivo in rats.2. Materials and methods
2.1. Animals
Male Sprague-Dawley rats aged 7 to 9 weeks (180-
200 g) were procured from the central animal facility,
Piramal Life Sciences, Mumbai. Animals were housed in
individually ventilated cages at a room temperature of
22°C ± 2°C, humidity 55% ± 5%, with a 12-hour/12-hour
light/dark cycle and had access to water and standard chow
(Amrut Laboratory Animal Feed, Sangli, India; protein,
22.12%; fat, 4.13%; and carbohydrate, 55.43%) or 60%
fructose-enriched diet (D 0011301; Research Diets, New
Brunswick, NJ) ad libitum. The guidelines of the Commit-tee for the Purpose of Control and Supervision on
Experiments on Animals, Government of India, were
followed; and all experimental procedures were approved
by the Animal Ethics Committee.
2.2. Chemicals and reagents
GPR40 agonist compound 1 (3-[4-{4-chlorobenzyla-
mino}phenyl] propanoic acid) was synthesized at the
Department of Medicinal Chemistry, Piramal Life Sciences,
Mumbai. Heparin was purchased from Biological E,
Hyderabad, India. All other chemicals were procured from
Sigma-Aldrich, St Louis, MO.
2.3. Oral glucose tolerance test
Glucose load (2 g/kg) was given orally to rats in this
study. Rats were mildly anesthetized for 1 to 2 minutes using
isoflurane anesthesia (3.5% vol/vol isoflurane in O2); and
about 80 μL of blood was collected from retroorbital plexus
into heparinized (20 U/mL) microcentrifuge tubes at
different time points, viz, −60, 0, 2, 5, 15, 30, 60, and
120 minutes. The plasma was separated by centrifugation at
6000g for 7 minutes at 4°C. Plasma was used immediately
for glucose estimation; an aliquot was stored at −20°C for
insulin estimation later.
2.4. Intraperitoneal glucose tolerance test
Incretin hormones are known to cause insulin secretion in
response to oral glucose [20]. To eliminate the incretin effect
on insulin secretion, glucose tolerance tests (GTTs) were also
performed by administering glucose through parenteral route
(intraperitoneal and intravenous). The same procedure was
followed as described for oral GTT (OGTT), except that
glucose load was administered by intraperitoneal route.
2.5. Intravenous glucose tolerance test
The same procedure was followed as described for
OGTT, except that a glucose load of 1.5 g/kg was
administered intravenously through rat-tail vein (volume of
injection, 1 mL/kg).
2.6. Treatment regimen
All the experiments were performed at 9:00 AM in the
morning on overnight-fasted animals unless otherwise stated
in protocol. Compound 1 and glibenclamide were prepared
as a suspension in 0.5% carboxymethylcellulose (CMC) with
25 μL Tween 80 and administered orally (1 mL/kg).
2.6.1. Effect of GPR40 receptor agonist on GSIS
To assess dose-dependent effect of compound 1 on GSIS,
overnight-fasted rats were randomly divided into 4 groups
and were subjected to an intraperitoneal GTT (IPGTT) as
described above. One of the following treatments was
assigned to each of the 4 groups: 0.5% CMC (1 mL/kg) or
50, 100, and 200 mg/kg of compound 1 given 1 hour before
intraperitoneal glucose load.
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and insulin in absence of glucose load
Overnight-fasted rats were randomly divided into
4 groups: 0.5% CMC (1 mL/kg) and compound 1 (50, 100,
and 200 mg/kg). The animals were bled before treatment at
0 minute and after treatment at 0.5, 1, 2, 4, 6, and 8 hours; and
plasma glucose and insulin were assessed as described below.
2.6.3. Effect of GPR40 receptor agonist on GSIS in GTTs
Overnight-fasted rats were randomly divided into
3 groups and were assigned treatments as follows: 0.5%
CMC (1 mL/kg), glibenclamide (30 mg/kg), and compound
1 (100 mg/kg); and the animals were subjected to OGTT,
IPGTT and intravenous GTT (IVGTT) as per the protocol
described above.
2.6.4. Effect of GPR40 receptor agonist on GSIS in fasted
and fed rats
Rats were randomly divided into 2 groups: 1 group was
fasted overnight, whereas the other group was fed with the
standard chow. Fed and fasted groups were further randomly
divided into 3 groups: 0.5% CMC (1 mL/kg), glibenclamide
(30 mg/kg), and compound 1 (100 mg/kg); and IPGTT was
performed. In addition, the study was repeated using
compound 1 at a dose of 180 mg/kg in fed rats.
2.6.5. Effect of GPR40 receptor agonist on GSIS in rats fed
a high-fructose diet
Insulin resistance was induced by chronic feeding of rats
for 8 weeks with 60% fructose-enriched diet. A group fed
normal pellet diet was also used that served as a control. Rats
fed a high-fructose diet were divided into 2 groups: 1 group
served as control (0.5% CMC, 1 mL/kg), whereas the other
group was treated with compound 1 (100 mg/kg). The
animals fed normal pellet diet and 60% high-fructose diet
were subjected to IPGTT as described above.
2.7. Biochemical estimation
Plasma glucose concentration was estimated immedi-
ately after sample collection using the glucose determina-
tion kits (DiaSys, Holzheim, Germany; glucose oxidase/
peroxidase [GOD/POD] enzymatic assay method) with a
Hitachi 902 biochemical autoanalyzer (Hitachi Science
Systems, Ibaraki, Japan). Plasma insulin was estimated
using an enzyme-linked immunosorbent assay kit as per the
manufacturer's instructions (Linco Research, St Charles,
MO). Insulinogenic index was estimated as per the
previously described method [21]. It was calculated by
taking the sum of the difference in plasma insulin at each
time point with respect to basal levels (up to 30 minutes)
and dividing it by the sum of the difference in plasma





R 30 DG2.8. Pharmacokinetic studies
Rats were randomized into 2 groups (n = 4 per group): 1
group was fasted overnight (∼16 hours), whereas the other
group was fed with normal diet. The fasted rats received an
oral dose of 100 mg/kg, whereas fed animals received 100,
140, 180, and 250 mg/kg of compound 1. Plasma concentra-
tions were determined by a high-performance liquid chroma-
tography method developed in our laboratory. Briefly, blood
was collected from retroorbital plexus under isoflurane
anesthesia in heparinized (20 U/mL) microcentrifuge tubes.
Plasma was obtained by centrifugation at 6000g for 7 minutes
at 4°C in a Sigma refrigerated centrifuge (model no. 3K30,
rotor no. 12153). Plasma samples were processed by
transferring a 150-μL quantity into a microcentrifuge tube
followed by equal volume of acetonitrile. The sample was
vortex mixed for 2 minutes and centrifuged at 9000g for
5 minutes. The supernatant was collected and subjected to
high-performance liquid chromatography analysis. The
chromatographic system consisted of a Waters 2695 Separa-
tions Module with 2996 Photodiode Array Detector (Waters,
Milford,MA). Separationwas carried out at room temperature
on a Waters X-Terra C18 column of 100 × 3 mm internal
diameter and a particle size of 5 μmol/L. Elution was carried
out with a gradient of 100% acetonitrile and 0.1%
trifluoroacetic acid at a flow rate of 1 mL/min. Ultraviolet
absorbance was monitored at photodiode array 3D Max plot
wavelength. The retention time for compound 1 was 5.8
minutes. Calibration curve was obtained by dissolving a
known quantity of compound 1 in rat plasma to obtain
concentrations ranging from 1 to 100 μg/mL. A linear
relationship (r2 = 0.9998) was obtained when peak areas were
plotted against plasma concentration. Coefficients of variation
were lower than 10%, whereas accuracy ranged from 90% to
110%. The detection limit of the method was 0.5 μg/mL.
2.9. Statistical analysis
All the results are expressed as mean ± SEM. Unpaired
Student t test (2-tailed) was performed for statistical analysis
of differences between mean values when comparisons were
made between 2 groups. When comparisons were to be made
between more than 2 groups, 1-way analysis of variance
followed by Tukey post hoc analysis was used. Furthermore,
for multiple comparisons of plasma glucose and insulin
values at individual time points between 3 groups, we
performed 1-way analysis of variance with repeated
measures with “time” as a “within factor” and “treatment
groups” as a “between factor.”3. Results
3.1. Effect of GPR40 receptor agonist on GSIS
The effect of compound 1 on plasma glucose, insulin, and
insulinogenic index in IPGTT is shown in Fig. 1 (A, B, and
C). Compound 1 reduced plasma glucose at 30 minutes at a
Fig. 1. Effect of GPR40 receptor agonist (50, 100, and 200 mg/kg) on
plasma glucose (A) and insulin release (B) in IPGTT in overnight-fasted rats.
Compound 1 was administered orally 1 hour before glucose load (2 g/kg,
intraperitoneal). Fig. 1 C illustrates insulinogenic index. Data represent
mean ± SEM of 6 rats. *P b .05 vs control group.
ig. 2. Effect of GPR40 receptor agonist on blood glucose and insulin
lease in overnight-fasted rats in the absence of glucose load. Effect of
ifferent doses of compound 1 (50, 100, and 200 mg/kg) on plasma glucose
) and insulin release (B). Data represent mean ± SEM of 6 rats. *P b .05 vs
control group.
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in insulin levels was observed at a dose of 100 (P b .05) and
200 mg/kg (P b .01) of compound 1. Insulinogenic index of
compound 1–treated animals at 100 and 200 mg/kg was
higher than that of control group (Fig. 1C). The increase
in insulinogenic index of compound 1 at both 100 and
200 mg/kg over the control group was similar; and hence, the
dose of 100 mg/kg was selected for further studies.3.2. Effect of GPR40 receptor agonist on plasma glucose
and insulin in fasted rats
In the absence of glucose load, compound 1 per se caused
significant glucose reduction at the dose of 100 and 200mg/kg
at 2 (P b .01) and 4 hours (100 mg/kg, P b .05; 200 mg/kg P b
.01; Fig. 2A). However, no significant change in insulin level
was observed at any of the doses tested (Fig. 2B).
3.3. Effect of GPR40 receptor agonist on GSIS in GTTs
3.3.1. Oral glucose tolerance test
Fig. 3A illustrates that compound 1 displayed better
glucose tolerance with significant (P b .05) glucose reduction
at 60 minutes as compared with control animals. In addition,
compound 1 treatment resulted in increase in plasma insulin
levels, with significant increase observed at 30 minutes (P b
.05) as compared with control group (Fig. 3B). Treatment of
compound 1 and glibenclamide potentiated GSIS as demon-
strated by the increase in insulinogenic index (Fig. 3C).
3.3.2. Intraperitoneal glucose tolerance test
In IPGTT, increase in plasma insulin levels was observed




Fig. 3. Effect of GPR40 receptor agonist on GSIS in overnight-fasted rats. Compound 1 (100 mg/kg) was administered orally 1 hour before glucose load (2 g/kg,
oral; or 2 g/kg, intraperitoneal; or 1.5 g/kg, intravenous). Glibenclamide (30 mg/kg, 1 hour prior) was used as a reference compound. Changes in blood glucose
level, corresponding insulin release, and insulinogenic index in OGTT (A-C), IPGTT (D-F), and IVGTT (G-I) studies. Data represent mean ± SEM of 6 rats. *P b
.05 and ***P b .001 vs respective control group.
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(5 minutes onward, P b .01) (Fig. 3D and E). This rise in
insulin secretion in terms of insulinogenic index was greater
in the compound 1–treated group when compared with that
of control group (Fig. 3F). In contrast, glibenclamide
improved glucose tolerance but did not exhibit insulin
release (Fig. 3D and E).
3.3.3. Intravenous glucose tolerance test
The intravenous glucose load of 1.5 g/kg caused the
plasma glucose to shoot up within 2 minutes to a high level
of 350 to 400 mg/dL (Fig. 3G) in the control group.
Compound 1 improved glucose tolerance. Plasma insulin
levels showed a peak at 5 minutes (P b .01), whereasreduction in plasma glucose was observed 15 minutes
onward (P b .01), suggesting that the released insulin
resulted in glucose reduction. As in IPGTT, glibenclamide
did not cause any significant rise in insulinogenic index
when compared with that of control group (Fig. 3I).
Compound 1 treatment resulted in higher insulinogenic
index than that of control group.
3.4. GPR40 receptor agonist potentiated GSIS in fasted and
fed rats
The basal levels of plasma glucose (fed vs fasted rats:
127.2 ± 3.9 vs 78.1 ± 3.5) and insulin (fed vs fasted rats:
0.85 ± 0.2 vs 0.40 ± 0.02) were higher in fed group (Fig. 4D
Fig. 4. Effect of GPR40 receptor agonist on GSIS in fasted or fed rats. Compound 1 (100 mg/kg) was administered orally 1 hour before glucose load (2 g/kg,
intraperitoneal) in fed or fasted rats. Glibenclamide (30 mg/kg, 1 hour prior) was used as a reference compound. Changes in blood glucose levels and
corresponding insulin release in fasted (A, B) and fed (D, E) rats. Insulinogenic index in fasted (C) and fed (F) states. Data represent mean ± SEM of 6 rats. *P b
.05 and **P b .01 vs respective control group.
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Fasting-induced impairment of GSIS was evident from the
insulinogenic index when compared with that of fed state
(Fig. 4C and F). Glibenclamide-treated animals displayed
reduction in plasma glucose and increased insulinogenic
index when compared with controls in fed group but not in
fasted group (Fig. 4C and F).On the other hand, compound
1 potentiated GSIS in fasted state but failed to do so in fed
state as is evident from insulinogenic index (Fig. 4C and F).
However, a careful assessment revealed that the rise inplasma insulin levels in fed animals in the compound 1–
treated group at 2 minutes was significantly higher (P b .05)
when compared with that in the controls (Fig. 4D and E).
Suspecting differential pharmacokinetics in fed and fasted
condition, a detailed pharmacokinetic evaluation was
performed, which revealed the low plasma concentration
of compound 1 in fed state (Fig. 5). As expected, increasing
dose of compound 1 improved its pharmacokinetic profile
in a dose-dependent manner. In fed state, compound 1 at
180 mg/kg exhibited a Cmax of 250.3 μg/mL and AUC0-last
Fig. 5. Pharmacokinetic profile of GPR40 receptor agonist in fasted or fed
rats. The oral absorption profile of compound 1 in fed (100, 140, 180, and
250mgkg) and fasted (100mg/kg) rats. Data represent mean ± SEM of 4 rats.
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(256.9 μg/mL) and AUC0-last (1022.2 μg*h/mL) of
compound 1 at 100 mg/kg in fasted state (Table 1).
Accordingly, we studied the effect of compound 1 on GSIS
at 180 mg/kg in fed state vs 100 mg/kg in fasted state.
Compound 1 (180 mg/kg) showed a significant decrease in
plasma glucose (P b .05) and an increase in insulin (P b .05)
levels as compared with controls in fed state (Fig. 6D and
E). Compound 1 also showed an increase in insulinogenic
index as compared with control group in both fed and fasted
state (Fig. 6C and F).
3.5. Improvement of GSIS by GPR40 receptor agonist in
rats fed a high-fructose diet
Feeding of animals with 60% fructose diet resulted in
significant glucose intolerance (P b .01 at 15, 30, and
60 minutes vs normal pellet diet control; Fig. 7A).
Furthermore, the group fed 60% high-fructose diet exhibited
reduced insulinogenic index (Fig. 7C), which was not
significant. Treatment with compound 1 (100 mg/kg)
potentiated GSIS as indicated by the rise in the insulinogenic
index (Fig. 7B and C).able 1
harmacokinetic parameters after oral administration of compound 1 in fed
00, 140, 180, and 250 mg/kg) and fasted (100 mg/kg) state in rats
Compound 1 (mg/kg)
arameters Fasted state Fed state
100 100 140 180 250
max (μg/mL) 256.93 96.75 175.26 250.29 307.04
max (h) 0.50 1.00 2.00 2.00 2.00
UC0-last (μg*h/mL) 1022.22 388.21 880.40 1068.80 1863.15
UC0-∞ (μg*h/mL) 1067.17 443.19 957.14 1156.81 2521.45
alf-life (h) 1.54 2.50 1.72 1.87 3.76
ata represent mean values of 4 rats.4. Discussion
Recently, the GPR40 receptor involvement in glucose
homeostasis has generated much interest because of the
discovery of FFAs as its endogenous ligands [22]. Several in
vitro and ex vivo studies show that acute stimulation of
GPR40 receptor with fatty acids (ie, palmitate, intralipid)
potentiates GSIS [7,9,10]. However, potentiation of GSIS by
FFA is compromised in chronically FFA elevated states such
as insulin resistance induced by feeding of a high-fructose
diet to rats [18]. Recently, small molecule GPR40 receptor
agonists were shown to potentiate glucose-dependent insulinsecretion in MIN6 cell line [13] and in pancreatic islets, and
improved glucose tolerance in mice [19]. However, whether
GPR40 receptor activation results in potentiation of GSIS in
vivo in rats is not known. Therefore, by using small molecule
agonist, we assessed the effect of GPR40 receptor activation
on GSIS in normal and pathophysiologic conditions in rats.
We found that GPR40 receptor activation results in
potentiation of GSIS in fasted, in fed, and, most importantly,
in insulin-resistant rats.
In OGTT, compound 1 showed better glucose tolerance
and significantly improved plasma insulin levels, suggesting
potentiation of GSIS. Potentiation of GSIS was also observed
in IPGTT and IVGTT. In these studies, increase in insulin
level in compound 1–treated group precedes the glucose
reduction, which implies that potentiation of GSIS is
responsible for improved glucose tolerance. Interestingly, in
GTTs, the insulin level in agonist-treated groups was directly
proportional to the rate of rise and peak levels of glucose in
control group (ie, intravenous or intraperitoneal insulin
release compared with oral). Tan and associates [19] have
also observed increase in plasma insulin level at early time
point and improved glucose tolerance in mice. Glibenclami-
de's insulinotropic action is compromised in fasted animals in
IPGTTand IVGTT. There is evidence in literature suggesting
that fasting compromises the insulin secretory response of
glibenclamide and tolbutamide [23]. However, in OGTT,
insulin release in glibenclamide-treated animals is higher as
compared with that in controls. The plausible explanation to
this observation is that, in OGTT, the observed insulin release
is a synergistic action of both glibenclamide and incretin
hormones released upon oral glucose load [24]. Despite the
lack of insulin release, glibenclamide improved glucose
tolerance in fasted animals, which might be through
extrapancreatic mechanisms like nonoxidative glucose dis-
posal and increased glucose transport [25-27].
In the absence of glucose load, compound 1 dose
dependently lowered glucose, but without associated change
in insulin levels. Immunohistochemical and messenger RNA
studies have demonstrated that GPR40 receptors are
expressed specifically in the rat pancreatic tissue and rodent
pancreatic β-cell lines (MIN6, βTC-3, HIT-T15, and
RINm5F) [5,7]. Therefore, the observed glucose reduction










Fig. 6. Effect of GPR40 receptor agonist on GSIS in fed and fasted rats at doses resulting in similar plasma exposure. Compound 1 was administered orally 1 hour
before glucose load (2 g/kg, intraperitoneal). Fasted rats were administered a dose of 100 mg/kg and fed animals with a dose of 180 mg/kg, resulting in a
comparable pharmacokinetic profile. Changes in blood glucose levels, corresponding insulin release, and insulinogenic index for fasted (A-C) and fed (D-F) rats.
Data represent mean ± SEM of 6 rats. *P b .05, **P b .01 vs respective control group.
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GPR40 receptor agonist potentiates insulin release in a
glucose-dependent manner. In contrast, Flodgren and
co-workers [28] have reported that GPR40 is present on α-
cells and causes glucagon release. In the same study, linolenic
acid (a endogenous agonist of GPR40) shows a dose-
dependent glucagon release at both low and high concentra-
tions of glucose. It is thereby expected that released glucagon,
after GPR40 receptor agonist treatment, should result in
increase in glucose levels. However, our studies showed a
dose-dependent reduction in glucose preceded by insulinrelease in the GTT (Fig. 1A-C). It may be likely that the β-cell
effect might be overriding a subtle effect mediated by α-cells
because, in normal physiology, the β-cell population in islets
is higher than that of α-cells. Nevertheless, further studies
are needed for better understanding of this observation.
It is well known that fasting causes impairment of GSIS.
The impairment of GSIS was shown to be due to increased β-
oxidation and reduced esterification of FFA in fasted state,
thus making them unavailable for insulin exocytosis through
formation of complex lipids [1,29]. In our study, we found
that there was a marked impairment of GSIS in fasting state
Fig. 7. Effect of GPR40 receptor agonist on GSIS in rats fed with 60% high-
fructose diet for 8 weeks. The rats were subjected to IPGTT after overnight
fasting. Compound 1 (100 mg/kg) was administered orally 1 hour before
glucose load (2 g/kg, intraperitoneal). Changes in blood glucose levels (A),
corresponding insulin release (B), and insulinogenic index (C) in rats fed
60% fructose diet. Data represent mean ± SEM of 6 rats. *P b .05 vs group
fed 60% high-fructose diet.
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reported that circulating FFA is essential for GSIS in fasting
state in rats.
Although it is very clear that intracellular actions of FFA
get compromised in fasting state, the role of extracellular
GPR40 receptor–mediated actions in GSIS in fasting state is
not yet known. Hence, in the present study, we examined the
role of GPR40 receptor stimulation by compound 1 on GSIS
in both fasting and fed state. Compound 1 treatment resultedin potentiation of GSIS in fasted state and, upon increasing
the dose, in fed state as well. In contrast, glibenclamide
potentiation of GSIS is compromised in fasting state. This
observation is in line with previous studies where intrave-
nous glibenclamide showed reduced insulin release in fasted
rats [23]. Glibenclamide's insulin secretory action involves
intracellular mechanisms because 90% of its binding sites are
located inside the β-cell [31]. Moreover, both glucose and
glibenclamide stimulate insulin release by inhibiting carni-
tine palmitoyltransferase 1 activity, which switches fatty acid
metabolism from β-oxidation to protein kinase C–dependent
insulin exocytosis. Recent studies have shown that the ability
of glibenclamide and malonyl-CoA to inhibit carnitine
palmitoyltransferase 1 gets impaired during fasting [32]. In
view of our results with GPR40 receptor agonist in fed and
fasted state and the fact that glibenclamide and glucose
(which act mainly by intracellular pathway) fail to potentiate/
mediate GSIS in fasted state, we infer that GSIS impairment
induced by fasting involves alteration in intracellular FFA
action rather than modulation in GPR40 receptor signaling.
The acute stimulating effect of FFA on GSIS has been
well described both in vitro [33,34] and in vivo [35]. In
contrast, several in vitro studies in β-cell lines and in rodent
and human islets have confirmed that insulin secretion at
high glucose concentration is impaired in a time-dependent
manner by chronic exposure to FFA. Islets from prediabetic
Zucker diabetic fatty rats and from fructose-fed insulin-
resistant rats appear to be more susceptible to this FFA-
mediated desensitization of GSIS [36,18]. Although deleter-
ious effects of long-term exposure of FFA on glucose
tolerance have been well studied, the role of GPR40 receptor
in these conditions is still not clear. There are contradicting
reports regarding involvement of GPR40 receptor in
impaired glucose tolerance associated with insulin-resistant
condition. According to Steneberg and coworkers [37],
GPR40−/− deletion confers protection against obesity-
induced hyperinsulinemia, hyperglycemia, and glucose
intolerance, whereas Latour and associates [12] demon-
strated that deleterious effects of FFA on GSIS were similar
in both GPR40−/− and wild-type mice islets, indicating that
GPR40 receptor does not mediate the long-term deleterious
effects of FFA. In our study, we observed that chronic
feeding with 60% fructose diet to rats resulted in impaired
glucose tolerance. This implies that rats chronically fed a diet
containing 60% fructose were insulin resistant. Treatment
with GPR40 receptor agonist enhanced insulin release,
resulting in improved glucose tolerance. Improvement in
glucose tolerance in mice fed a high-fat diet using GPR40
receptor agonist was reported by Tan and associates [19].
These findings indicate that GPR40 receptor agonist
potentiates GSIS even in insulin-resistant condition.
In conclusion, our study for the first time shows that acute
administration of a small molecule GPR40 receptor agonist
results in potentiation of GSIS in vivo in rats fed a normal
and a chronic high-fructose diet. The potentiation of GSIS in
high fructose diet–induced insulin-resistant rats suggests that
342 L.S. Doshi et al. / Metabolism Clinical and Experimental 58 (2009) 333–343the actions of GPR40 receptor are intact even in states of
chronically elevated FFA. Unlike sulfonylureas, GPR40
receptor agonist potentiated GSIS; and therefore, it may not
cause severe hypoglycemia. Exposure to isoflurane is known
to cause glucose intolerance [38]. However, prolonged
exposure causes acute hyperglycemia in fed but not in fasted
rats [39]. In this study, except in 1 experiment (Fig. 6),
animals were fasted overnight and all the rats were exposed
to isoflurane anesthesia for a brief period. Therefore, the
effect of isoflurane on glucose tolerance is expected to be
minimal and, if any, will be same across all the groups.
Further studies are in progress to determine whether chronic
administration of GPR40 receptor agonist improves fasting
glucose and diabetic complications in animal models of
diabetes. Nevertheless, these findings together suggest that
GPR40 receptor agonist may offer a novel treatment option
to control postprandial hyperglycemia.
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